All In Biotech

Free tool

FAERS Monitor: Vegzelma

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761268 or its brand name (Vegzelma, Bevacizumab-Adcd). Reports on generic versions are filed under their own applications.

Reports

203

Serious

184

91% of reports

Hospitalization

74

Death reported

22

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • intentional product use issue28
  • neutropenia27
  • diarrhoea18
  • neuropathy peripheral16
  • pyrexia13
  • asthenia12
  • thrombocytopenia12
  • nausea11
  • drug ineffective9
  • vomiting9
  • decreased appetite8
  • headache8
  • therapy cessation8
  • intentional dose omission7
  • leukopenia7

Reports by year received

View as table
YearReports
20234
202421
202578
2026100

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,956 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intentional product use issueSignal2833.123.5844
intentional dose omissionSignal725.412.3141
neutropeniaSignal2720.614.5487
neuropathy peripheralSignal1617.410.9233
therapy cessationSignal816.18.299
leukopeniaSignal714.57.075
thrombocytopeniaSignal1211.16.4101
pyrexiaSignal133.92.326
decreased appetiteSignal83.61.812
astheniaSignal123.31.917
diarrhoeaSignal182.91.921
vomiting92.01.04
nausea111.40.81
headache81.30.70
drug ineffective90.70.41

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.